Radioactive drug for advanced PD-L1 positive solid tumors
Part of Cancer, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a radioactive medicine (177Lu-anti-PD-L1 sdAb) that delivers radiation to cancer cells with PD-L1 protein, which is found on some solid tumors. It is for people whose cancer has spread or come back after standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and willing to follow all study procedures.
- Your cancer must be one of these types: non-small cell lung cancer, small cell lung cancer, triple-negative breast cancer, melanoma, head and neck cancer, endometrial cancer, or a cancer with MMR deficiency or MSI-high status.
- Your cancer must have PD-L1 protein (or you must be willing to have a tumor sample tested for it).
- You must have tried at least one standard treatment (like immunotherapy) and it stopped working, or you have decided not to take standard treatments.
- You need to have at least one tumor that can be measured on a scan, and you must be able to lie still for imaging.
- Your kidney, liver, and blood cell counts must be within safe limits as determined by your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug called [177Lu]Lu-DFC413 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target cancer cells with a specific marker seen on a special scan.
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
This trial tests a new radioactive drug (177Lu-NNS309) for people with advanced pancreatic, lung, breast, or colorectal cancer that has not responded to prior treatments. It aims to see if the drug can target and shrink tumors.
This trial tests a new drug that delivers radiation directly to cancer cells that have a specific marker called HER2. It may be an option for patients whose cancer has grown despite other treatments.
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
This trial tests a new radioactive drug (177Lu-AB-3PRGD2) that targets a protein called integrin αvβ3 found on many solid tumors. It is for people whose cancer has not responded to or has come back after several standard treatments.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.